Oncology

Onsolis provides opioid tolerant patients with an alternative dosing option.

Screening evaluates a large number of cells used in cancer therapy.

Research advances personalized cancer therapy.

Religion and spirituality can have a positive impact on cancer outcomes.

FDA-approved drug is now a first-line treatment for select patients with EGFR non-small cell lung cancer.

New treatment approach many help control inflammation.

Research may help to target which patients will respond to specific chemotherapy drugs.

Inhibiting oxygen sensor leads to a reduced spread of breast cancer throughout the body.

Patient experiences complete remission after treatment with 2 immunotherapies.

Patient who make multiple trips to their general practitioner before getting a diagnosis are more likely to respond negatively to other aspects of their care.

Test targets non-small cell lung cancer patients with an acquired resistant mutation.

Nivolumab shows promise in patients whose disease progressed after ipilimumab and BRAF inhibitor therapy.

Catch up with the latest developments in cancer research.

Weight cycling may influence the biological processes that can lead to cancer.

Process improves the accuracy of cancer treatments.

High cost of research and development causes less investment by pharmaceutical firms.

Researchers predict the progression of the cancer based on its expression of IL13RA2.

Active surveillance increases in prevalence.

Study finds significant barriers to health care access, including stigmatization.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Studies show inexpensive, generic drugs can help reduce breast cancer mortality in postmenopausal women.

Long-term survival results after 5 years of ipilimumab therapy in patients with advanced melanoma shows promise.

Novel oral soluble film is indicated to prevent highly and moderately emetogenic chemotherapy-induced nausea and vomiting.

Toradol may limit ability of tumor cells to grow and spread.

Toxin may inhibit cell division in cancerous cells.

Results of the long-awaited Keynote 006 study prove the superiority of pembrolizumab to ipilimumab on criteria of both progression-free survival and overall survival.

Destabilized cell metabolism can lead to the creation of tumors.

Contamination with particulate matter can lead to inflammation, allergic reaction, and blood vessel blockage.

Iressa blocks the activity of an enzyme responsible for regulating pathways implicated in the growth and survival of cancer cells.